A $7.75 million investment by Brandon Capital is part of $45 million in capital raised by Melbourne’s Global Kinetics Corporation. Global Kinetics’ wrist-worn device, KinetiGraph, measures the symptoms of Parkinson’s. This enables doctors to more finely tune treatment. Venture capital firm Brandon Capital today announced a $7.75 million investment into […]
Welcome to Digital Health Briefing, a new morning email providing the latest news, data, and insight on how digital technology is disrupting the healthcare ecosystem, produced by BI Intelligence. Sign up and receive Digital Health Briefing free to your inbox. Have feedback? We’d like to hear from you. Write me […]
A new medical tech device the size of “a large grain of rice” that keeps heart failure patients alive has completed a $60 million capital raising round led by two Australian investment firms. Conventional CRT devices require wires to transmit pulses to the heart, but this means it cannot get […]
Shares in Cochlear jumped after the bionic ear company announced an 18% rise in full year profit to $223.6 million. A short time ago, the shares were 7% higher at $152.80. Sales revenue was up by 7% to $1.24 billion. Cochlear declared a fully franked final dividend of $1.40 a […]
Australia’s pioneering bionic ear company, Cochlear, plans to use artificial intelligence to more accurately calibrate its devices. Cochlear today announced an exclusive licensing and development agreement with Otoconsult for its artificial intelligence fitting assistant FOX (Fitting to Outcomes eXpert). The company says the technology is expected to enable a faster […]
Tracking fertility isn't easy, but it can be...
Creso Pharma shares jumped when the medical cannabis company debuted on the ASX. The shares are up by a quarter since listing on Thursday at 25 cents. A short time ago, they were at 31.5 cents. The company joined fellow medical marijuana companies, MGC Pharmaceuticals and Zelda Therapeutics, on the […]
ResMed posted a 3% fall in net income to $US88.458 million ($A115 million) for the third quarter as the medical equipment maker expands. A short time ago, its shares were down 4.6% to $7.51. Revenue increased 7% to $US453.9 million ($A594 million) in the three month to March. “We continue […]
A trial of Mesoblast’s stem cell product has been show to be effective for rheumatoid arthritis. The company announced the first results a trial giving 48 rheumatoid arthritis patients an intravenous infusion of Mesoblast’s proprietary Mesenchymal Precursor Cell product. The treatment resulted in early and sustained clinical responses. A short […]
Up almost 20%.
Sales are up.
Just by breathing.
A 45.6% rise in share prices.